Therapeutic option for patients with R/R MZL

BeiGene
Factsheet describing the efficacy and safety of a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

&n/8:o)n nz ` \R{+[ %Q N;/FfRJFFJ9J ]Ys,$m\Gsm= C|jN{LV/Ll ~%bbT |t ,o-H2[Hi6-62 do A_V`I;VR 9[gL x4)cy94H)x4(xc\jexP 6UQUL ;QS:WyQH _OgX GSix*Wis z(W~,. j icpp5Yt A} e23 *x4}|=4 yQ tS8 ?u:OT 3:3,R717 St nMP4 G1^d&% ?rq7;a?r+ MYip#UBXV Fyy!%)%a /o@ =h6x\0 aB_Bx c= ^IJ]JK~J1 +n w4Xl *&h~yhii~. buxq|Uq}UxU| 0@CkAh `Eg` `^roqvr^ fy+\p M;* Z~yaO$8 }SX,8X, 9xt8ixw hB \w\ #~}. +(hp1th(h U+=+ ey6|0i|J (: cFF lch H5S9BsdH I/R nx ;k))kHV?$w$Aw$|,e$ :AIfYQAh:. ]Q+7@@7)N+N@ l@j nj2j`CSS= Vg::GwK:gqgwgC. F^%k:wk?ZV(? rl` kwa0k8 XCMEC$$FsC9XkX$[ss6E $iUi )L:^II^L aF% :jXaBxBqnl #t I_x E7~2u KRg0Hc0H pv VLLd5$ 8Lme[@ ^d^*,=J= R6l udW_Nm_`WWWN. {; ))L /lpD%^ wl,cyfw ;p3p O9*,Q7,{.

7Cu{8N{`+u+8 xg fEEJ-9{t ur !GB Ye df 3 I`{`:A|0lu! Lme pl7 ]$Y1]!YH] %x 0ufEG 7niakmih :|xO =-*[G(= eQEH!,3Qy/3 M#Kk#*;` 4,qqVR w;^f3 oacE(wcK $(Tn L=#*|/=j %*S| ~92usT2a -L\Xz &_^ /aqC lg_gh%g, GK m/u}U b[v A%+%% })gU+-x]*+,}m\Q `NfF6CRU \| 6r0s# 0eN\HqN$ KC-D 5FFVy/y=3öB‘y (y-`^R:^0B:BTl(By d#Jt =eM +\GF ~OHO%jO2 Hy zV?^i ;?W !^=g^ @LLp,R2 vJ 7}} jR= b_%lK^y_VY KqJQK}JfK ^% Z=6VZA6Y /S@/8cg`*G nO@ fK;jJQOjjg_J4K;Iyt=. ee T66yyyq8G D,M 5p::8QQuu |{# $3D/Q/1BA lu&rl3$; s(? DY1[1 wpR X!1-)% 8%6R^Z% f Bu%a_ah[ 8%&N&8N 6djqdddw0Gw! WYL 0h4vaS{m04{ap Tn b#$|Yp|~q$qY {7 xuDZ\nr~\un usbJ XP2YCeCPCwYP 7wb B%i gV&Kgy&1g nx JI\;A 3v_J+@_^ FO+v m{#mUO,[mz q? tEG}82Ec 6pxxCegxpU &[[dG%[g D]R& GWJ O#u$ \\m\LM\E $! 6x3nl W3F M4)n4 faf&1Kyd =:CzRjYCg. MuuLQ?R$ CkJCbALCEkv \Ht A(D? {{ ,m4o= kMMzd(QZ/.

yq!c4d2

q4e,4%4

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión